GAITHERSBURG, Md., Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Conference Details: | |||||
Fireside Chat | |||||
Date: | Wednesday, November 15, 2023 | ||||
Time: | 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) | ||||
Location: | London | ||||
Moderator: | Roger Song, M.D., CFA, Equity Analyst | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Wednesday, November 15, 2023 | ||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.63 |
| Daily Change: | -0.37 -4.11 |
| Daily Volume: | 3,758,255 |
| Market Cap: | US$1.380B |
December 13, 2024 December 10, 2024 November 11, 2024 October 16, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
